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Abstract
Background: Designing maximally selective ligands that act on individual targets is the dominant paradigm in
drug discovery. Poor selectivity can underlie toxicity and side effects in the clinic, and for this reason compound
selectivity is increasingly monitored from very early on in the drug discovery process. To make sense of large
amounts of profiling data, and to determine when a compound is sufficiently selective, there is a need for a
proper quantitative measure of selectivity.
Results: Here we propose a new theoretical entropy score that can be calculated from a set of IC50 data. In
contrast to previous measures such as the ‘selectivity score’, Gini score, or partition index, the entropy score is non-
arbitary, fully exploits IC50 data, and is not dependent on a reference enzyme. In addition, the entropy score gives
the most robust values with data from different sources, because it is less sensitive to errors. We apply the new
score to kinase and nuclear receptor profiling data, and to high-throughput screening data. In addition, through
analyzing profiles of clinical compounds, we show quantitatively that a more selective kinase inhibitor is not
necessarily more drug-like.
Conclusions: For quantifying selectivity from panel profiling, a theoretical entropy score is the best method. It is
valuable for studying the molecular mechanisms of selectivity, and to steer compound progression in drug
discovery programs.
Background
In recent years, the kinase field has developed the prac-
tice of monitoring inhibitor selectivity through profiling
on panels of biochemical assays [1-7], and other fields
are following this example [8,9]. Such profiling means
that scientists are faced with increasing amounts of data
that need to be distilled into human sense. It would be
p o w e r f u lt oh a v eag o o ds i n g l es e l e c t i v i t yv a l u ef o r
quantitatively steering the drug discovery process, for
measuring progress of series within a program, for com-
putational drug design [10-12], and for establishing
when a compound is sufficiently selective. However, in
contrast to, for instance, lipophilicity and potency,
where values such as logP or binding constant (Kd)a r e
guiding, quantitative measures for selectivity are still
under debate. Often graphic methods are used to give
insight, for example dotting a kinome tree [13,14], heat
maps [4,6], or a radius plot, but such methods only
allow qualitative comparison of a limited set of com-
pounds at a time.
To make quantitative selectivity comparisons, three
notable methods have been proposed (Figure 1). The
first is the ‘selectivity score’ [5], which simply divides
the number of kinases hit at an arbitrary Kd or IC50
value (e.g. 3 μM) by the number of kinases tested (S
(3 μM), Figure 1a). A related score is S(10x), which
divides the number of kinases hit at 10 times the Kd of
the target by the number of kinases tested [5]. The dis-
advantage of both methods is that 3 μM, or the factor
10, is an arbitrary cut-off value. For example, take two
inhibitors, one that binds to two kinases with Kdso f
1n Ma n d1μM, and another with Kdso f1n Ma n d
1 nM. Both are ranked equally specific by both S(3 μM)
and S(10x), whereas the first compound is clearly more
specific.
A less arbitrary parameter for selectivity is the Gini
score [15]. This uses %-inhibition data at a single inhibi-
tor concentration. These data are rank-ordered, summed
and normalized (Figure 1b) to arrive at a cumulative
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lated by the relative area outside the curve (Figure 1b).
Though this solves the problem with the selectivity
score, it leaves other disadvantages. One is that the Gini
score has no conceptual or thermodynamic meaning
such as a Kd value has. Another is that it performs sub-
optimally with smaller profiling panels [16]. In addition,
the use of %-inhibition data makes the value more
dependent on experimental conditions than a Kd-based
score [15]. For instance, profiling with 1 μM inhibitor
concentration results in higher percentages inhibition
than using 0.1 μM of inhibitor. The 1 μM test therefore
yields a more promiscuous Gini value, requiring the
arbitrary 1 μM to be mentioned when calculating Gini
scores. The same goes for concentrations of ATP or
other co-factors. This is confusing and limits compari-
sons across profiles.
A recently proposed method is the partition index
[16]. This selects a reference kinase (usually the most
potently hit one), and calculates the fraction of inhibitor
molecules that would bind this kinase, in an imaginary
pool of all panel kinases (Figure 1c). The partition index
(Pmax)i saK d-based score with a thermodynamical
underpinning, and performs well when test panels are
Figure 1 Four ways to measure selectivity. (a) The ‘selectivity score’ [5] is expressed as a fraction, as signified by the pie chart, and calculated
by the formula given. (b) The four steps in calculation of the Gini coefficient [15] are indicated top-left inside the panel. For simplicity, a 3-
protein example is used. The graph shows Gini scores from two inhibitor profiles on 100 kinases. The A’-profile is more specific. The area A’ is
larger than area A, and therefore the coefficient is larger. (c) The partition coefficient [16] is a ratio of association constants. The numbers 1, 2, 3...
refer to kinases in the profiling panel. If n is a kinase number, then Ka, n is defined as 1/Kd,n. (d) The selectivity entropy. The various colors
represent different proteins, and the hexagon a compound. Top: a selective compound binds almost exclusively to one protein, resulting in a
narrow distribution across protein species. Bottom: a promiscuous compound binds to many different proteins, resulting in a broad distribution
across protein species. The distribution can be quantified using Gibb’s entropy definition (the formula shown).
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it doesn’t characterize the complete inhibitor distribu-
tion in the imaginary kinase mixture, but just the frac-
tion bound to the reference enzyme. Consider two
inhibitors: A binds to 11 kinases, one with a Kd of 1 nM
and ten others at 10 nM. Inhibitor B binds to 2 kinases,
both with Kds of 1 nM. The partition index would score
both inhibitors as equally specific (Pmax = 0.5), whereas
the second is intuitively more specific. Another down-
side is the necessary choice of a reference kinase. If an
inhibitor is relevant in two projects, it can have two dif-
ferent Pmax values. Moreover, because the score is rela-
tive to a particular kinase, the error on the Kd of this
reference kinase dominates the error in the partition
index. Ideally, in panel profiling, the errors on all Kds
are equally weighted.
Here we propose a novel selectivity metric without
these disadvantages. Our method is based on the princi-
ple that, when confronted with multiple kinases, inhibi-
tor molecules will assume a Boltzmann distribution over
the various targets (Figure 1d). The broadness of this
distribution can be assessed through a theoretical
entropy calculation (it is not actually measuring
entropy). We show the advantages of this method and
some applications. Because it can be used with any
activity profiling dataset, it is a universal parameter for
expressing selectivity.
Results and discussion
Theory
Imagine a theoretical mixture of all protein targets on
which selectivity was assessed. No competing factors are
present such as ATP. To this mixture we add a small
amount of inhibitor, in such a way that approximately
all inhibitor molecules are bound by targets, and no par-
ticular binding site gets saturated. A selective inhibitor
will bind to one target almost exclusively and have a
narrow distribution (low entropy, Figure 1d). A promis-
cuous inhibitor will bind to many targets and have a
broad distribution (high entropy, Figure 1d). The broad-
ness of the inhibitor distribution on the target mixture
reflects the selectivity of the compound.
The binding of one inhibitor molecule to a particular
protein can be seen as a thermodynamical state with an
energy level determined by Kd (through ΔG=R T l n K d).
F o rs i m p l i c i t yw eu s et h et e r mK d to represent both Kd
and Ki. The distribution of molecules over these energy
states is given by the Boltzmann law. As the broadness
of a Boltzmann distribution is measured by entropy, the
selectivity implied in the distributions of Figure 1d can
be captured in an entropy.
A similar insight is given by information theory. It is
well-established that information can be quantified
using entropy [17]. A selective kinase inhibitor can be
seen as containing more information about which active
site to bind than a promiscuous inhibitor. The selectivity
difference between the inhibitors can therefore be quan-
tified by information entropy.
The distribution of a compound across energy states is
given by the Boltzmann formula [18]:
φ1 = e− G1/kT/

i
e− Gi/kT
(1)
Where j1 is the fraction of molecules occupying state
1, and ΔG1 is the free energy of occupying state 1 when
the inhibitor comes from solution. In order to arrive at
a fraction, the denominator in equation (1) contains the
summation of occupancies of all states, which are
labelled i, with free energies ΔGi.
In general, entropy can be calculated from fractions of
all l states using the Gibbs formula [18]:
Ssel = −

l
φl lnφl (2)
Ssel is shorthand for selectivity entropy. Compared to
the original Gibbs formulation, equation (2) contains a
minus sign on the right hand to ensure that Ssel is a
positive value. Now, we need to evaluate equation (2)
from a set of measurements. For this we need
 Gi =R Tl nK d,i = −RT ln Ka,i (3)
Where Ka,i is the association constant of the inhibitor
to target (or state) i, which is the inverse of the binding
constant Kd,i (which is a dissociation constant). In short:
Ka,i =1 / K d,i. If we express the free energy in units of ‘per
molecule’ rather than ‘per mole’, equation (3) becomes
 Gi = −kT ln Ka,i (4)
and equation (1) can be rewritten as
φ1 = ekT lnKa,1/kT/

i
ekT lnKa,i/kT
⇔ elnKa,1/

i
elnKa,i =K a,1/

i
Ka,i
(5)
Using this result in equation (2) gives
Ssel = −

l
(Ka,l/

i
Ka,i)ln(Ka,l/

i
(Ka,i) (6)
Simplifying notation gives
Ssel = − a(Ka/ K) ln (Ka/ K) (7)
Equation (7) defines how a selectivity entropy can be
calculated from a collection of association constants Ka.
Here ΣK is the sum of all association constants.
It is most simple to apply equation (7) to directly
measured binding constants or inhibition constants.
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ful if they are related to Kd. Fortunately, for kinases it is
standard to measure IC50 values at [ATP] = KM,ATP. Ide-
ally, such IC50se q u a l2t i m e sK d, according to the
Cheng-Prusoff equation [19,20]. The factor 2 will drop
out in equation (7), and we therefore can use data of
the format IC50-at-KM, ATP directly as if they were Kd.
Protocol for calculating a selectivity entropy
From the above, it follows that a selectivity entropy can
be quickly calculated from a set of profiling data with
the following protocol:
1. Generate Ka values by taking 1/Kd or 1/IC50
2. Add all Ka values to obtain ΣK
3. For every Ka, calculate Ka/ΣK
4. For every Ka, evaluate (Ka/ΣK) ln (Ka/ΣK)
5. Sum all terms and multiply by -1
This process can be easily automated for use with
large datasets [21] or internal databases.
Examples
The selectivity entropy is based on calculating the
entropy of the hypothetical inhibitor distribution in a
protein mixture. To give more insights into the proper-
ties of this metric, some examples are useful.
An inhibitor that only binds to a single kinase with a
Kd of 1 nM (Ka =1 0
9 M
-1)h a sK a/ΣKa =1 .T h e nS sel =
-[1 ln 1]= 0, which is the lowest possibly entropy.
An inhibitor that binds to two kinases (X and Y) with
aK d of 1 nM has Kx/ΣKa =K y/ΣKa = 0.5 and a selectiv-
ity entropy of -[0.5 ln 0.5 + 0.5 ln 0.5] = 0.69. Thus
lower selectivity results in higher entropy.
If we modify the compound such that it still inhibits
kinase X with a Kd of 1 nM, but inhibits less strongly
kinase Y with a Kd of 1 μM, then the new inhibitor is
more specific. Now Kx/ΣKa =1 0
9/(10
9+10
6)a n dK y/ΣKa
=1 0
6/(10
9+10
6), resulting in Ssel = -[0.999 ln 0.999 +
0.001 ln 0.001] = 0.0079. This is less than 0.69. This
shows that the selectivity entropy can distinguish in the
case where the selectivity scores S(3 μM) and S(10x)
cannot (see above).
A less selective inhibitor that binds three targets with
Kdso f1n M ,h a sS sel = -3·[0.3 ln 0.3 ] = 1.08, and an
even more promiscuous inhibitor that binds 5 targets, of
which 3 at 1 nM, and 2 at 1 μM, has ΣK = 3·10
9+2 · 1 0
6
= 3.002·10
9 and Ssel =- 3 · [ 1 · 1 0
9/3·10
9 ln 1·10
9/3·10
9 ]+
2·[1·10
6/3·10
9 ln 1·10
6/3·10
9 ] = 3.07. Thus Ssel gradually
increases when more targets are more potently hit.
If we take the inhibitors A and B that were mentioned
earlier, then A (with an inhibition profile of 1 nM, and
ten times 10 nM), has ΣK = 1·10
9+ 10·10
8 =2 · 1 0
9 and
Ssel =-[ 1 · 1 0
9/2·10
9 ln 1·10
9/2·10
9 ] + 10·[1·10
8/2·10
9 ln
1·10
8/2·10
9 ] = 1.84. This is a more aselective value than
inhibitor B with an inhibition profile of twice 1 nM,
which has Ssel = 0.69 (see above). Thus the selectivity
entropy can distinguish in a case where the partition
coefficient Pmax cannot.
Comparison to other methods
Having defined the entropy, we next investigated its per-
formance relative to the most widely-used methods, on
a public profiling dataset of 38 inhibitors on 290 non-
mutant kinases [5] (Table 1 and Additional file 1). The
values for Gini score, S(3 μM), S(10x) and partition
coefficient, were taken from earlier work [16]. To this
we added a Ka-Gini value and the selectivity entropy.
The Ka-Gini is a Gini score directly calculated on Kas,
without reverting to %-inhibition values (see below).
From each of these scores we determined an inhibitor
selectivity ranking, and a rank order difference com-
pared to the entropy method (Uitdehaag_S1). In addi-
tion, to get an overview of the profiling raw data [5], we
appended an activity-based heat map (Uitdehaag_S1).
From the rankings it is apparent that each of the ear-
lier methods such as the classic Gini score, S(3 μM) and
S(10x) generate considerable ranking differences com-
pared to all other methods. This was observed earlier
[16]. For the Gini score, this is related to the conversion
from IC50 to %-inhibition, because the Ka-Gini gives
more consistent rankings. For the S(3 μM) and the S
( 1 0 x ) ,t h eu s eo fac u t - o f fi sl i k e l yt o oc o a r s ea n
approach. For instance in the case of S(10x), there are
six inhibitors with a score of 0, making it impossible to
distinguish between those highly specific compounds.
The newer methods such as Pmax,K a-Gini, and the
selectivity entropy, give a more consistent ranking
between them. For example, all three methods have PI-
103, CI-1033, GW2580, VX-745 and gefitinib in their
selectivity top five. There are differences however, most
strikingly illustrated by the inhibitor SB-431542. This is
ranked by Pmax as 31
st most selective, but by Ka-Gini
and the selectivity entropy as 15
th and 14
th (Uitde-
haag_S1). Also S(3 μM )r a n k st h i sA L K 5i n h i b i t o r[ 2 2 ]
as selective. However, SB-431542 hits four kinases with
very similar IC50s between 100-300 nM, which leads to
a broad partitioning over these kinases, resulting in a
very promiscuous Pmax of 0.14. The partition coefficient
therefore ranks SB-431542 as almost equally selective to
sunitinib (Pmax = 0.11, rank 33). Nevertheless, sunitinib
inhibits 181 kinases below 3 μM, and SB-431542 only 5.
T h e r e f o r ew et h i n kt h a tK a-Gini and the selectivity
e n t r o p ya r eab e t t e r‘general’ measure of selectivity in
this case.
Another inhibitor scored differently is MLN-518 [23],
which ranks 26
st by Pmax,b u t1 4
th and 15
th by Ka-Gini
and the selectivity entropy (Table 1 and Uitdehaag_S1).
Again, these differences arise because this inhibitor hits
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nM, leading to a promiscuous Pmax (0.26). However,
MLN-518 only hits 10 kinases below 3 μM, making it
intuitively more selective than e.g. ZD-6474 [24] (Pmax =
0.28, ranked 25
th by Pmax), which hits 79 kinases below
3 μM. These cases illustrate the earlier point that Pmax
underscores inhibitors that only hit a few kinases at
comparable potencies. The Gini score and selectivity
entropy assign a higher selectivity to these cases.
Finally, any selectivity score should be in line with the
visual ranking from a heat map. The Additional file 1
shows that, generally, compounds with a higher entropy
indeed have a busier heat map. A few exceptions stand
out, which by eye appear more promiscuous than their
entropy ranking indicates, for instance SU-14813, suniti-
nib and staurosporin. However, these compounds have
extreme low Kds on selected targets (SU-14813: 0.29
nM on PDGFRb, sunitinib: 0.075 nM on PDGFRb,
staurosporin: 0.037 nM on LOK and 0.024 nM on SLK).
Therefore they are relatively selective over activities in
the 1-100 nM range, whereas these activities still fall
within the highlighted ranges in Uitdehaag_S1. In a
sense, the large dynamic range of the data limits visual
assessment through a heat map.
Consistency across profiling methods
As a next step we selected 16 compounds from the pub-
lic profile (Ambit) [5], and measured activity data on
these using a different profiling service (Millipore, data
available as Additional file 2). The 16 compounds repre-
sent a diversity of molecular scaffolds, promiscuity and
target classes (Table 2). Also for these new data, we cal-
culated the selectivity metrics (Uitdehaag_S2). In the
ideal case, the selectivity values are similar irrespective
of profiling technology (in the same way that a Kd value
Table 1 Selectivity metrics calculated for the Ambit
kinase profiling dataset
code Gini S3uM S10x Pmax Ka-Gini entropies
PI-103 0.41 0.00 0.00 0.97 0.99 0.05
CI-1033 0.72 0.15 0.00 0.88 0.99 0.17
GW-2580 0.54 0.01 0.00 0.92 0.99 0.26
VX-745 0.51 0.03 0.00 0.92 0.99 0.28
Gefitinib 0.65 0.07 0.00 0.89 0.99 0.44
Lapatinib 0.57 0.01 0.00 0.70 0.99 0.70
Erlotinib 0.75 0.15 0.00 0.67 0.99 0.88
EKB-569 0.78 0.18 0.00 0.67 0.99 0.89
Imatinib 0.79 0.07 0.02 0.65 0.99 1.05
CP-724714 0.49 0.02 0.01 0.33 0.99 1.10
CP-690550 0.66 0.03 0.01 0.50 0.99 1.11
BIRB-796 0.81 0.16 0.00 0.47 0.99 1.15
PTK-787 0.71 0.03 0.02 0.44 0.98 1.54
SB-431542 0.42 0.02 0.01 0.14 0.98 1.56
MLN-518 0.74 0.06 0.01 0.26 0.98 1.58
LY-333531 0.76 0.16 0.01 0.42 0.98 1.68
CHIR-258 0.76 0.33 0.01 0.44 0.97 1.80
AZD1152HQPA 0.78 0.10 0.02 0.34 0.98 1.91
ABT-869 0.82 0.16 0.01 0.32 0.98 1.93
MLN-8054 0.75 0.13 0.01 0.36 0.97 1.95
Roscovitine 0.33 0.03 0.03 0.12 0.98 2.02
SU-14813 0.70 0.51 0.02 0.18 0.97 2.04
Sunitinib 0.67 0.57 0.02 0.11 0.97 2.05
GW-786034 0.80 0.21 0.02 0.33 0.97 2.06
SB-202190 0.76 0.09 0.02 0.35 0.97 2.08
Sorafenib 0.82 0.18 0.10 0.46 0.97 2.15
SB-203580 0.77 0.10 0.02 0.24 0.97 2.26
AMG-706 0.82 0.09 0.04 0.22 0.97 2.36
SNS-032 0.80 0.13 0.06 0.30 0.97 2.44
CHIR265 0.74 0.13 0.12 0.36 0.96 2.47
Flavopiridol 0.77 0.19 0.17 0.42 0.95 2.50
AST-487 0.73 0.45 0.04 0.11 0.95 2.74
ZD-6474 0.79 0.27 0.26 0.28 0.94 2.88
Staurosporine 0.35 0.87 0.50 0.02 0.93 2.91
VX-680 0.76 0.38 0.03 0.15 0.93 3.09
Dasatinib 0.79 0.28 0.10 0.03 0.93 3.21
PKC-412 0.71 0.47 0.08 0.10 0.88 3.72
JNJ-7706621 0.74 0.37 0.08 0.10 0.87 3.73
Values for various selectivity metrics. In the Additional file 1, this table is
extended with compound rank ordering and rank differences, and colour
coded for clarity.
Table 2 16 compounds used to check the robustness of
the selectivity metrics
code name structure
ABT-869 / AL-39324 linifanib
AZD-1152HQPA barasertib
AZD-6474 vandetanib
BAY43-9006 sorafenib
BIRB-796 doramapimod
BMS-345825 dasatinib
CP-690550 tasocitinib
MK-0457 / VX-680 tozasertib
MLN-518 / CT-53518 tandutinib
MLN-8054 -
PI 103 -
RAF-265 / CHIR-265 -
SB 203580 -
STI-571 imatinib
SU-11248 sunitinib
VX-745 -
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The data of both methods are plotted in Figure 2.
All metrics except the entropy and Pmax tend to be quite
unevenly distributed. For instance all Ka-Gini scores fall
between 0.93 and 1.00, where they can theoretically
range from 0 to 1. If we nevertheless calculate the corre-
lation statistics between both datasets, the R-square
from linear regression and the correlation indicate that
the selectivity entropy, S(3 μM) and Ka-Gini are the
most robust methods (Figure 2).
It would be ideal if the absolute value of the metrics
could also be compared between datasets. This means
that a specificity of e.g. 1.2 in the first profile, would
also score 1.2 in the second profile. To get insight in
this, we calculated the best fit to a 1:1 correlation (the
diagonal line in Figure 2), using normalized data. The
Ka-Gini score was rescaled to its useful range of 0.93-
1.00 (see legend to Figure 2), and then fitted. The S(3
μM) and the selectivity entropy have the best fit. The
fact that here the Ka-Gini performs poorer is probably
caused by the use of cumulative inhibition values
(Figure 1b), which leads to the accumulation of errors
(as pointed out in ref. 16).
In all fits, the Pmax a n dS ( 1 0 x )s c o r e ss h o ww o r s ef i t s
and more scatter, indicating that these methods generate
more error in their final value. For S(10x) and for Pmax,
this is because both methods make use of a reference
value, usually the most potent IC50, and errors in this
reference value propagate more than errors in other
IC50s. Ideally, for S(10x) and Pmax, the reference value
specifically would have to be more accurately
established.
If all analyses are taken together, the selectivity
entropy avoids many pitfalls of the other methods (see
above), shows consistent compound ranking (Table 1,
Uitdehaag_S1), and is among the most robust methods
across profiling datasets (Figure 2). For this reason, we
propose the entropy method as the best metric for gen-
eral selectivity.
Defining average selectivity
Quantification of selectivity helps to define when a com-
pound is selective or promiscuous. Because of its consis-
tency, the entropy method is ideally suited for
benchmarking selectivity values. In the 290-kinase pro-
filing dataset, the entropies are monomodally distribu-
ted, with an average of 1.8 (median of 1.9) and a
standard deviation (s) of 1.0 (not shown). Based on the
correlation in Figure 2, it is expected that these statistics
will be conserved in other profiling sets. Therefore, in
general, a kinase compound with an entropy less than
about 2 can be called selective, and more than 2 promis-
cuous. This provides a first quantitative definition of
kinase selectivity.
Selectivity of allosteric inhibitors
It is generally thought that allosteric kinase inhibitors
(known as type II, type III, or DFG-out inhibitors) are
more selective [25,26]. The selectivity entropy now
allows quantitative testing of this idea. We identified,
from literature, which inhibitors in the profiling datasets
are type II and III, based on X-ray structures. Sorafenib
induces the kinase DFG-out conformation in B-RAF
[27], nilotinib and gleevec in Abl [28], GW-2580 in Fms
[29] and BIRB-796 in p38a [30]. Lapatinib induces a C-
helix shift in EGFR [31]. PD-0325901 [32] and AZD-
6244 induce a C-helix shift in MEK1 [32]. All other
kinase inhibitors in the profile were labelled type I.
Comparing the entropy distributions in both samples
shows that type II/III inhibitors have significantly lower
entropies (Figure 3a). Although other factors, such as
t h et i m ea tw h i c hac o m p o u n dw a sd e v e l o p e d ,c o u l d
influence the entropy differences, the correlation
between low entropy and allostery strongly supports the
focus on allostery for developing specific inhibitors
[25,26].
Among the specific inhibitors in the type I category,
3D-structures of PI-103, CI-1033 and VX-745 bound to
their targets have not been determined. Therefore,
Figure 2 Correlation between specificity values calculated from different datasets. All x-axes: scores from binding data from the Ambit
kinase dataset [5]. All y-axes: scores from activity data measured on the same compounds at Millipore. We calculated (in Microsoft Excel, for
panels from left to right) the R-squares from linear regression as: 0.93, 0.92, 0.99, 0.54, 0.81 and the correlation coefficients as: 0.81, 0.90, 0.75, 0.57,
0.63. The straight line represents the ideal case of specificity values being insensitive to profiling method. The total squared distance of
(normalized) data points to the straight line is given in the top left corner of each panel. For this latter calculation, data were normalized by
dividing all values by the highest value in their set. Because the Ka-Gini values are very unevenly distributed, the lowest value 0.93 was first
subtracted from all data in this set. Irrespective of statistical method, the selectivity entropy, S(3 μM) and Ka-Gini are the most robust metrics.
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ficity from a form of undiscovered induced fit. Indeed,
VX-745-related compounds induce a peptide flip near
Met109/Gly110 in P38a [33]. Of the five most selective
compounds in Table 1, only gefitinib so far is undoubt-
edly a type I inhibitor [34], making this EGFR inhibitor
an interesting model for the structural biology of non-
allosteric specificity.
Use of selectivity measures in nuclear receptor profiling
Selectivity profiling is most advanced in the kinase field,
but is emerging in other fields. To illustrate that selec-
tivity metrics such as the entropy can also be used with
other target families, we investigated a long-standing
question in the nuclear receptor field: are non-steroidal
ligands more selective than steroidals? [35]. For this, we
calculated the entropies of a published profile of 35
antagonists on a panel of 6 steroid receptors [9] (the
androgen receptor, estrogen receptor a,e s t r o g e n
receptor b, mineralocorticoid receptor, glucocorticoid
receptor, and progesterone receptor). This shows that
there are no statistically significant selectivity differences
between steroidals and non-steroidals (Figure 3b). A
more important determinant for selectivity could be, in
parallel to kinase inhibitors, if a ligand induces a confor-
mational change. Indeed, many nuclear receptor ago-
nists are known to induce a transformation from a
flexible receptor to a rigid agonistic form [36-40], or a
heterodimer form [41,42]. In contrast, antagonists are
know to displace helix 12 specifically from the agonistic
form [36]. Thus, the large role of induced fit in ligand
binding to nuclear receptors might explain the relative
high selectivity of these ligands [9,36,43,44].
Use in hit prioritization
Aside from solving questions in the structure-function
area, the selectivity entropy can be used during drug dis-
covery. Previously it has been shown that selectivity
Figure 3 Applications of selectivity entropy. (a) Inhibitors that modify kinase conformation have higher selectivity. (b) Non-steroidal nuclear
receptor antagonists are not more selective than steroidal antagonists. OHflu: hydroxyflutamide, ralx: raloxifene, 4OHT: 4-hydroxytamoxifen, PPT:
propyl pyrazole triol, DES: diethylstilbestrol. Horizontal lines and dotted lines in panels (a) and (b) represent the average and median of each set,
respectively. P values of two-tailed student-t tests are indicated. (c) Rank-ordering of hit selectivity in a panel of regulators of G-protein signalling.
(d) Selectivity entropy of kinase inhibitors in clinical phase. Black bars: average entropy in that class. Light grey to white bars: averages restricted
to oncology. Dark to light grey bars: averages for compounds of which the phase I trials were initiated before 2005. Error bars indicate one
standard deviation. Numbers of datapoints used (column left to right): 10/8/6, 6/6/4, 6/4/4, 8/8/7. The discontinued class represent compounds
that underwent clinical testing but were stopped. For the post-2005 projects, discontinued compounds have a lower entropy than the
combined set of Phase III and launched compounds. As the number of non-oncology compounds is 2, 0, 2, 0 for each clinical bin respectively,
this dataset only allows conclusions for the field of oncology.
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classify compounds, set targets, and rationalize improve-
ment [16]. In addition, metrics such as the entropy are
useful in evaluating screening data, especially now
screening larger compound collections in parallel assays
is increasingly popular.
We downloaded PubChem data of 59 compounds
tested in a panel of four assays for regulators of G pro-
tein signalling (RGS) [21].T h e s ed a t aw e r es e l e c t e d
b e c a u s et h e yw e r ep u b l i c l ya v a i l a b l ea n dw e r en e i t h e ra
kinase nor a nuclear receptor panel. In addition the data
were dose-response, were all in a similar assay format,
and were ran in the same lab with the same compound
set.
We calculated the compound entropies across the
RGS panel, and used them for ranking, which immedi-
ately distinguishes the scaffolds that are specific (Figure
3c). The best are ID 24785302, a pyrazole-phenoxy deri-
vative, and ID 24834029, a bicyclo-octane derivative,
which are likely to be better lead optimization starting
points than more promiscuous scaffolds. Triaging com-
pounds by entropy is a far more time-efficient and
unbiased way than manual evaluation of four parallel
columns of data. Indeed, listing of the selectivity entropy
in public databases of screening data would provide
users with immediate information on scaffold
promiscuity.
Selectivity and clinical outcome
Finally, the selectivity entropy can be used to study clin-
ical success. Selective compounds are generated because
they are thought to be less toxic and therefore better
doseable to effective ranges [45]. To test the hypothesis
that clinically approved inhibitors are more selective, we
binned the compounds in the public kinase profile [5]
according to their clinical history, and calculated their
average entropies (Figure 3d, Additional file 3). Com-
pared to the average discontinued compound, the aver-
age marketed kinase inhibitor is not more selective, and
the average Phase III compound is even significantly
more aselective. To exclude therapy area effects, we also
performed the analysis for compounds in the oncology
area, which is the only therapeutic area with a statisti-
cally significant amount of projects. This leads to a simi-
lar conclusion (Figure 3d). To exclude effects of time
from this analysis (more recently invented kinase inhibi-
tors might be more selective, because of advances in the
kinase field), we repeated the analysis for compounds
that entered clinical phase I before 2005. This shows
even more clearly that more succesful compounds are, if
anything, more broadly selective (Figure 3d).
Behind such statistics lies the success of, for instance,
the spectrum selective drugs dasatinib, sorafenib and
sunitinib (an average entropy of 3.13), and the failure of
the highly selective MEK-targeted drugs PD-0325901
and CI-1040 (an average entropy of 0.32). Because 66-
100% of the analysed compounds in each clinical bin are
(or were) developed for oncology, our conclusion is pri-
marily valid for oncology, until more kinase inhibitors
enter the clinic for other indications. Nevertheless, the
finding that a selective kinase inhibitor has fewer
chances of surviving early clinical trials fuels the notion
that polypharmacology is sometimes required to achieve
effect (in oncology) [45-47].
Conclusions
In order to quantify compound selectivity as a single
value, based on data from profiling in parallel assays, we
have presented a selectivity entropy method, and com-
pared this to other existing methods. The best method
should avoid artifacts that obscure compound ranking,
and show consistent values across profiling methods.
Based on these criteria, the selectivity entropy is the
best method.
A few cautionary notes are in order. First, the method
is labelled an entropy in the sense of information theory
[17], which is different to entropy in the sense of vibra-
tional modes in enzyme active sites. Whereas these
vibrations can form a physical basis for selectivity
[39,48,49], our method is a computational metric to
condense large datasets.
Secondly, any selectivity metric that produces a gen-
eral value does not take into account the specific impor-
tance of individual targets. Therefore, the entropy is
useful for generally characterizing tool compounds and
drug candidates, but if particular targets need to be hit,
or avoided, the Kds on these individual targets need to
be monitored. It is possible to calculate an entropy on
any particular panel of all-important targets, or to assign
a weighing factor to every kinase, as suggested for Pmax
[16] and calculate a weighted entropy. However, the
practicality of this needs to be assessed.
Next, it is good custom to perform profiling in bio-
chemical assays at [ATP] = KM-ATP,b e c a u s et h i sg e n e r -
ates IC50s that are directly related to the ATP-
independent Kd value. However, in a cellular environ-
ment, there is a constant high (~5 mM) ATP concentra-
tion and therefore a biochemically selective inhibitor
will act with different specificity in a cell. If the inhibitor
has a specificity for a target with a KM,ATP above the
panel average, then that inhibitor will act even more
specifically in a cell and vice versa (KM,ATP values can
generally be found on websites of profiling research
organizations). Selectivity inside the cell is also deter-
mined by factors such as cellular penetration, comparti-
mentalization and metabolic activity [39]. Therefore,
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step in developing selective inhibitors.
Another point is that any selectivity metric is always
associated with the assay panel used, and the entropy
value will change if an inhibited protein is added to the
panel. Adding a protein that does not bind inhibitor will
not affect the entropy value. In this way the discovery of
new inhibitor targets by e.g. pulldown experiments, can
change the idea of inhibitor selectivity, and also the
entropy value. A good example is PI-103, the most
selective inhibitor in Table 1, which in the literature is
known as a dual PI3-kinase/mTOR inhibitor [50], and
which appears specific in Table 1 because PI3-kinase is
not incorporated in the profiling panel.
In addition, an inhibitor that hits 2 kinases at 1 nM
from a panel of 10 has the same selectivity entropy as
an inhibitor that inhibits 2 kinases at 1 nM in a panel of
100. However, intuitively, the second inhibitor is more
specific (the ‘selectivity score’ differentiates in this case).
This illustrates that it is important to compare entropy
scores on similar panels. At the same time, when results
from different panels are weighed, as in the example, it
s h o u l dn o tb ea s s u m e df o rt h ef i r s ti n h i b i t o r ,t h a ti ti s
inactive against all 90 other kinases in the second panel.
It would be better to assign an average Kd where mea-
surements are missing. In that case the first inhibitor
w o u l ds c o r eam o r ep r o m i s c u o u se n t r o p yc o m p a r e dt o
the second inhibitor.
F i n a l l yi tm u s tb es t r e s s e dt h a tt h es e l e c t i v i t ye n t r o p y
could be applied in many more fields. It could, for
instance, be a useful metric in the computational studies
that attempt to link compound in vitro safety profiles to
compound characteristics [51-53]. Currently, that field
uses various forms of ‘promiscuity scores’ which bear
similarity to the selectivity score. A more robust and
non-arbitrary metric such as the selectivity entropy
could be of help in building more detailed pharmacolo-
gical models of compound activity-selectivity relation-
ships [51-53].
In summary, the selectivity entropy is a very useful
tool for making sense of large arrays of profiling data.
We have demonstrated its use in characterizing tool
compounds and drug candidates. Many more applica-
tions are imaginable in fields where an array of data is
available and the selectivity of a response needs to be
assessed. In that sense, the selectivity entropy is a gen-
eral aid in the study of selectivity.
Methods
Calculation of other selectivity scores
For comparisons between currently used methods, we
calculated the selectivity scores S(3 μM )a n dS ( 1 0 x )a s
outlined above and in ref. 5. The partition coefficient
Pmax was calculated as originally proposed [16], by taking
the Ka value of the most potently hit kinase, and dividing
it by Σ Ka. It is worth to note that the partition coefficient
is the same as jl in our entropy equation (eq. 2).
The Gini score was calculated from data on %-inhibi-
t i o n[ 1 5 ] .I nF i g u r e1 b ,t h e s ed a t aw e r ee x t r a c t e df r o m
Kd values using the Hill expression: %-inhibition = 100/
(1+10
-(pKd - pconc)), where pKd =- l o g( K d)a n dp c o n c=
-log (inhibitor concentration evaluated). In addition, to
work more directly with Kds ,w ea l s oi n t r o d u c eaK a-
Gini score, in which association constants are used for
rank-ordering the kinase profile. From this Ka-rank
ordering, a cumulative effect is calculated and normal-
ized, after which the areas are determined, in the same
way as for the original Gini score [15]. All calculations
were done in Microsoft Excel.
Sources of existing and new data
For our comparative rank-ordering (Table 1, Uitde-
haag_S1) we used the publicly available dataset released
by Ambit http://www.ambitbio.com, which contains
binding data (Kds) of 38 inhibitors on 290 kinases
(excluding mutants), and which is currently the largest
single profiling set available [5].
For comparing profiles across methods (Figure 2), we
selected 16 kinase inhibitors of the Ambit profile
(Table 2) and submitted these to the kinase profiling
service from Millipore (http://www.millipore.com/drug-
discovery/svp3/kpservices, data available as Additional
file 2). Both profiling methods are described earlier
[3,5,14] and differ (among other variations) in the fol-
lowing way: Ambit uses a competitive binding setup in
absence of ATP on kinases from T7 or HEK293
expression systems [14]. Millipore uses a radioactive
filter binding activity assay, with kinases purified from
Escherichia coli or baculovirus expression systems [3].
All Millipore profiling was done on 222 human kinases
at [ATP] = KM,ATP.
For comparing inhibitors with an allosteric (actually:
induced fit) profile (Figure 3a), we used data from the
Ambit profile [5], supplemented with Millipore profiling
data on nilotinib, PD-0325901 and AZD6244, because
these important inhibitors were lacking in the Ambit
dataset (data available in Additional file 2).
For comparing nuclear receptor data (Figure 3b), we
used the published profiling dataset of 35 inhibitors on
a panel consisting of all six steroid hormone receptors
[9] The data we used were EC50s in cell-based assays.
For evaluation of a screening dataset (Figure 3c), we
selected data from the PubChem initiative, determined
at the University of New Mexico on regulators of G pro-
tein signalling (isoforms 4, 19, 7 and 16. Assay identi-
fiers: 1872, 1884, 1888 and 1869) [21].
For evaluating clinical success (Figure 3d), we
tracked the clinical status of each compound in the
Uitdehaag and Zaman BMC Bioinformatics 2011, 12:94
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® database
(status February 2011, analysis availabe as Additional
file 3).
Additional material
Additional file 1: Selectivity metrics, heat maps, and selectivity rank
ordering for the Ambit profiling dataset (an extension of Table 1).
Additional file 2: EC50 values and selectivity metrics from an
activity based profiling of 16 reference inhibitors.
Additional file 3: Selectivity entropy and status of clinically tested
kinase inhibitors.
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